Popular Trials
Mesenchymal Stem Cells
Stem Cell Therapy for ALS
This trial will test the safety and efficacy of delivering MSCs to the CSF of people with ALS every 3 months for a total of 4 injections over 12 months. The goal of the study is to determine if this treatment is safe and can improve the subject's ALS symptoms.
PTC857 for ALS
This trial is testing a new drug called PTC857 to see if it can help people with ALS. Participants will either receive PTC857 or a non-active substance. If they complete the initial treatment, they can continue taking PTC857 for an extended period to further assess its effects.
Stem Cell Therapy
CNS10-NPC-GDNF for ALS
This trial is testing the safety of placing special cells into the brains of ALS patients. These cells release a protein that helps brain cells stay alive and healthy. The study aims to see if this new treatment is safe for people.
Rho Kinase Inhibitor
Rho Kinase Inhibitor for ALS
This trial is testing a new drug called WP-0512 to see if it can help people with ALS. It targets patients who have had ALS symptoms for a few years and meet specific health criteria. The drug aims to slow down the progression of ALS symptoms.
Herbal Medicine
TJ-68 for ALS
This trial is testing if a new drug called TJ-68 is safe and effective for improving muscle cramps in people with ALS. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the drug or the placebo.
Popular Filters
Trials for ALS Patients
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Trials for Brain Stem Stroke Patients
Neurostimulation Device
Implantation of brain-computer interface for communication in ALS, quadriplegia, and Locked In Syndrome
This trial will test a brain-computer interface that consists of platinum grids being implanted in the brain to pick up neural signals. Up to 128 channels will be used to test this interface for six months.
Behavioural Intervention
Neurosleeve for Arm Weakness/Paralysis
This trial is testing the NuroSleeve, a wearable device that helps people with weak or paralyzed arms move them using electrical signals. It is aimed at those who haven't fully recovered with standard therapies. The device detects small muscle movements and uses them to activate the brace and stimulate muscles, helping with arm movement. Electrical stimulation has been explored in various contexts, including improving arm and hand function in individuals with spinal cord injuries and post-stroke patients.
Phase 3 Trials
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Antisense Oligonucleotide
ION363 for ALS
This trial is testing a new drug called ION363 to help people with a specific genetic form of ALS (FUS-ALS). The study will see if the drug can help these patients live longer and maintain their abilities better. Participants will receive the drug for a period of time, then all will get the drug for an extended duration.
Trials With No Placebo
T-cell Therapy
RAPA-501 Therapy for ALS
This trial tests a new treatment for ALS using a patient's own immune cells that are modified to reduce inflammation. It targets ALS patients who have not progressed beyond certain limits. The goal is to see if this treatment is safe and effective.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Neurostimulation Device
Implantation of brain-computer interface for communication in ALS, quadriplegia, and Locked In Syndrome
This trial will test a brain-computer interface that consists of platinum grids being implanted in the brain to pick up neural signals. Up to 128 channels will be used to test this interface for six months.
View More Related Trials
Frequently Asked Questions
Introduction to als
What are the top hospitals conducting als research?
When it comes to advancing the understanding and treatment of amyotrophic lateral sclerosis (ALS), several hospitals have emerged as pioneers in clinical trials. Massachusetts General Hospital, located in the vibrant city of Boston, is at the forefront with an impressive ten ongoing ALS trials and a remarkable history of 62 completed studies dedicated to this challenging condition. Since conducting their first trial in 2001, they have been relentless in their pursuit to find effective treatments.
In Toronto, Sunnybrook Health Sciences Centre has become a beacon of hope for individuals living with ALS. With five active clinical trials underway and thirteen previously conducted studies since their inaugural trial in 2014, they are making significant strides towards unraveling the mysteries surrounding this devastating disease.
Down south in Jacksonville, Florida's Mayo Clinic is also lending its expertise to fight against ALS. They currently have five active clinical trials and a total of fifteen past endeavors under their belt since embarking on their first study in 2003. Their dedication extends beyond geographical boundaries as they contribute valuable knowledge to the global community.
Similarly invested is Emory University situated amidst Atlanta's bustling medical landscape. Alongside offering top-notch care for patients with ALS, Emory University actively engages in five ongoing clinical trials while having accomplished nineteen previous investigations since recording its initial trial back in 2003.
Meanwhile Augusta University boasts a more recent contribution but one that should not be underestimated; starting from just four existing current experiments until now gradually accumulating eight researches over time ever since taking up its maiden endeavor only six years ago back around2016
These institutions represent beacons of hope for those affected by ALS worldwide – each bringing unique perspectives and expertise to unravel this complex condition further. By dedicating themselves wholeheartedly to these critical research efforts, these hospitals pave the way towards finding better treatments and ultimately enhancing the lives of countless individuals impacted by ALS
Which are the best cities for als clinical trials?
When it comes to ALS clinical trials, several cities stand out as hubs for research and development. Boston, Massachusetts leads the way with 21 active trials investigating promising treatments like BIIB105, Pridopidine, and Baricitinib. New york City follows closely behind with 16 ongoing studies focused on SAR443820, Part D: Open-Label Treatment, dalfampridine, and other potential therapies. Baltimore, Maryland also emerges as a significant player in ALS research with 15 active trials exploring treatments such as BIIB105 and Pegcetacoplan (APL-2). Together with Toronto's 14 active trials studying various interventions including Part D: Open-Label Treatment and San Francisco's investigations into PTC857, Pridopidine, and ANX005; these cities offer individuals affected by ALS access to cutting-edge clinical trials that hold promise for advancing treatment options.
Which are the top treatments for als being explored in clinical trials?
Exciting advancements are taking place in ALS research, with several top treatments being explored in clinical trials. DNL343 is currently leading the pack with two active trials dedicated to ALS. This promising treatment made its debut in 2020 and has already gained recognition for its potential. Another contender, PTC857, is making waves with one ongoing trial focused on ALS after being first listed just this year (2022). Additionally, AP-101 shows promise as it undergoes an active trial for ALS treatment. Since its introduction in 2019, it has been involved in a total of two clinical trials dedicated to combating this debilitating disease. These innovative therapies offer hope to those affected by ALS and bring us closer to finding effective solutions for this challenging condition.
What are the most recent clinical trials for als?
Exciting developments are underway in the field of amyotrophic lateral sclerosis (ALS) research, with recent clinical trials offering promising prospects for patients. One notable trial is evaluating the potential of DNL343 to treat ALS, with both Phase 2 and Phase 3 studies currently underway since May 24, 2023. Another study worth mentioning is investigating CK0803 as a treatment option for ALS patients, following its availability in April 2023 during Phase 1 trials. Additionally, ABBV-CLS-7262 has shown promise in treating ALS and is progressing through Phase 2 and Phase 3 studies since March 23, 2023. This evolving landscape offers renewed hope to individuals affected by ALS as researchers strive towards finding effective treatments for this debilitating condition.
What als clinical trials were recently completed?
In the realm of ALS clinical trials, several noteworthy studies have recently achieved completion, bringing hope to those affected by this challenging condition. Merit E. Cudkowicz, MD spearheaded a trial investigating Pridopidine that concluded in December 2020. Another promising therapy, AMX0035, underwent testing sponsored by Amylyx Pharmaceuticals Inc., with results becoming available in November 2020. Moreover, Richard Bedlack, M.D., Ph.D., successfully completed a trial exploring Theracurmin HP in August 2020. Notably as well, Merit E. Cudkowicz was involved in multiple investigations that culminated around July 2020: CNM-Au8 study for potential treatment and Zilucoplan and Verdiperstat trials showcasing innovative approaches towards combating ALS symptoms. These significant advancements reflect the tireless efforts of researchers striving to conquer ALS and enhance patient outcomes.